We found that, after the energy-fixed breakfast, GLP-1 markedly enhanced satiety and fullness compared with placebo (Fig
We tailor these advanced GLP-1 receptor agonist therapies, including Ozempic, to each patient, ensuring individualized care that effectively supports diabetes management and cardiovascular risk reduction
A previous review of animal studies from the University of Amsterdam linked GLP-1 exposure during pregnancy to reduced fetal growth and skeletal abnormalities
While the bodys natural release of GLP-1 occurs briefly and only when food is present, these medications flood the system, leading to sustained metabolic effects
10.1002/ajmg.a.32308 67 Martnez-FrasM
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, La Brunner- Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F